Novocure trial misses primary survival endpoint
Novocure (NASDAQ:NVCR) announced that its Phase 3 TRIDENT trial evaluating Tumor Treating Fields (TTFields) therapy for glioblastoma did not achieve a statistically significant improvement in overall survival.










